08/18/2025
Absolutely remarkable 🩷
Laboratory research, notably led by Dr. Ciara Duffy at the Harry Perkins Institute of Medical Research in Perth, Australia, indicates that honeybee venom—specifically its key peptide melittin—can rapidly and selectively kill aggressive types of breast cancer cells, like triple‑negative and HER2‑enriched subtypes, while having minimal impact on normal, healthy cells.
In detail, these findings show that at a certain concentration, honeybee venom can induce 100% death of cancer cells within 60 minutes, and melittin can destroy cancer cell membranes swiftly.
Even within 20 minutes, melittin was found to substantially disrupt the growth-signaling pathways—like EGFR in triple-negative and HER2 in HER2‑enriched cancers—thus blocking the cancer cells’ ability to multiply and survive.
The research extended beyond in vitro (cell culture) to animal studies, where melittin combined with a chemotherapy drug (docetaxel) significantly reduced tumour growth in mice, suggesting potential synergy with conventional cancer treatments.
However, these are early-stage findings, based on lab and animal models. No clinical trials in humans have yet confirmed efficacy or safety in patients.
In fact, prominent medical authorities caution that while these results are promising, much more research is needed, especially considering potential risks, such as allergic or toxic reactions to bee venom—common concerns in apitherapy research.
